1,2,3-Propanetricarboxylic acid, 2-hydroxy-, zinc salt (2:3)
CAS 546-46-3
1,2,3-Propanetricarboxylic acid, 2-hydroxy-, zinc salt (2:3) (CAS 546-46-3) is a pharmaceutical compound with 0 bioactivity targets and 90 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
1,2,3-Propanetricarboxylic acid, 2-hydroxy-, zinc salt (2:3) is linked to DTXSID90889427 in DSSTox identifiers.
View industrial chemical data →Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, zinc salt (2:3) used for in pharmaceutical contexts?
1,2,3-Propanetricarboxylic acid, 2-hydroxy-, zinc salt (2:3) (CAS 546-46-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, zinc salt (2:3)?
1,2,3-Propanetricarboxylic acid, 2-hydroxy-, zinc salt (2:3) has 90 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal discomfort, Abdominal distension, Abdominal pain upper, Amyotrophic lateral sclerosis, Anxiety. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, zinc salt (2:3) also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Zinc Citrate with EU status "restricted".
What clinical phase is 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, zinc salt (2:3) in?
No phase 1-4 clinical development badge is rendered for 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, zinc salt (2:3) because the matched compound identifier rows do not contain a max-phase value.